N-[3-(2-氧代吡咯烷-1-基)丙基]乙酰胺 | 106692-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-[3-(2-氧代吡咯烷-1-基)丙基]乙酰胺
• 中文别名: 1,2,4,8,9-五氯二苯并[b,d]呋喃
• 英文名称: N-(3-acetamidopropyl)pyrrolidin-2-one
• 英文别名: N-[3-(2-oxopyrrolidin-1-yl)propyl]acetamide
• CAS: 106692-36-8
• 化学式: C₉H₁₆N₂O₂
• mdl: MFCD24388096
• 分子量: 184.238
• InChiKey: OAUYENAPBFTAQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(烯丙基氨基)丙腈 在 dirhodium tetraacetate 、 lithium aluminium tetrahydride 、 三丁基膦 、 氢气 作用下， 以 苯 为溶剂， 80.0 ℃ 、2.76 MPa 条件下， 反应 20.25h， 生成 N-[3-(2-氧代吡咯烷-1-基)丙基]乙酰胺
  参考文献：
  名称：

  Rhodium-catalysed hydroformylation and carbonylation of N-alkenyl-1,3-diaminopropanes

  摘要：

  The rhodium catalysed reactions of N-alkenyl-1,3-diaminopropanes with H-2/CO usually give mixtures of diazabicycloalkanes and aminopropyl lactams. The chemo-and regioselectivity of these reactions are influenced by the choice of ligand and by the ratio of H-2 and CO in the gas mixture and in some cases formation of a single compound can be achieved. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4020(97)10193-4

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS DE TRIAZOLOPYRIDINE DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040450A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A, Y and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了式（I）的化合物：其中A、Y和R1如规范中所定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• Thienopyrrole compound and use thereof as HCV polymerase inhibitor
  申请人：Mizojiri Ryo

  公开号：US20060167246A1

  公开（公告）日：2006-07-27

  The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]所表示的噻吡咯烷化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和含有该化合物作为活性成分的治疗剂。本发明的化合物基于HCV聚合酶抑制活性显示抗HCV活性，并且可用作丙型肝炎的预防或治疗剂。
• Control of chemo- and regio-selectivity in rhodium catalysed reactions of unsaturated amines with
  作者：David J. Bergmann、Eva M. Campi、W.Roy Jackson、Quentin J. McCubbin、Antonio F. Patti

  DOI：10.1016/s0040-4039(97)00889-7

  日期：1997.6

  The rhodium catalysed reactions of N-allyl- and N-butenyl-1,3-diaminopropanes give single products arising from exclusive hydroformylation at the terminal carbon when the hindered bisphosphite ligand, BIPHEPHOS is used. Reactions using a high carbon monoxide: hydrogen ratio (9:1) and triphenylphosphine as ligand give predominantly lactams arising from carbonylation but with poor control of regioselectivity

  当使用受阻的双亚磷酸酯配体BIPHEPHOS时，N-烯丙基和N-丁烯基-1,3-二氨基丙烷的铑催化反应产生的单一产物是由末端碳的独家加氢甲酰化产生的。使用高一氧化碳：氢比率（9：1）和三苯膦作为配体的反应主要产生内酰胺，这些内酰胺是由羰基化产生的，但对区域选择性的控制较差。
• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。